Akero Therapeutics

OverviewSuggest Edit

Akero Therapeutics develops medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. Akero's lead clinical program, AKR-001, is a long-acting Fc fusion modified FGF21 protein and potential treatment for NASH. AKR-001 builds upon two decades of work on FGF21 biology. It is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
TypePublic
Founded2017
HQSan Francisco, CA, US
Websiteakerotx.com

Latest Updates

Employees (est.) (Mar 2020)13(+63%)
Job Openings2
Share Price (Aug 2022)$12.8(+10%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Akero Therapeutics

Jonathan Young

Jonathan Young

Chief Operating Officer, Co-Founder
Mark Iwicki

Mark Iwicki

Chairman
William White

William White

Chief Financial Officer and Head of Corporate Development
Andrew Cheng

Andrew Cheng

President, Chief Executive Officer, Director
Kitty Yale

Kitty Yale

Chief Development Officer
Seth L. Harrison

Seth L. Harrison

Independent Board Member
Show more

Akero Therapeutics Office Locations

Akero Therapeutics has offices in San Francisco, Cambridge and South San Francisco
San Francisco, CA, US (HQ)
170 Harbor Way 3rd Floor
Cambridge, MA, US
400 Technology Square, 400 Technology Square 10th Floor
South San Francisco, CA, US
601 Gateway Blvd #350
Show all (3)

Akero Therapeutics Financials and Metrics

Akero Therapeutics Revenue

USD

Net income (Q1, 2022)

(26.0m)

EBIT (Q1, 2022)

(26.1m)

Market capitalization (4-Aug-2022)

407.7m

Closing stock price (4-Aug-2022)

12.8
Akero Therapeutics's current market capitalization is $407.7 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

General and administrative expense

1.1m1.9m8.6m15.2m19.1m

R&D expense

3.5m11.9m37.0m64.9m81.8m

Operating expense total

4.6m13.8m45.7m80.2m

EBIT

(4.6m)(13.8m)(45.7m)(80.2m)(100.9m)
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

General and administrative expense

2.4m3.6m3.4m4.5m5.0m4.9m5.5m

R&D expense

13.9m8.8m13.0m10.6m24.0m19.5m20.5m

Operating expense total

16.3m12.4m16.5m15.1m

EBIT

(16.3m)(12.4m)(16.5m)(15.1m)(29.0m)(24.4m)(26.1m)
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Cash

598.0k76.0m64.8m187.2m150.5m

Prepaid Expenses

40.0k1.2m1.6m3.0m5.3m

Current Assets

638.0k77.1m138.0m271.3m193.6m

PP&E

131.0k90.0k
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

147.8m47.2m63.2m188.0m157.5m164.9m

Prepaid Expenses

2.2m933.0k10.4m5.8m6.2m6.7m

Current Assets

150.1m126.2m113.2m255.8m236.2m221.8m

PP&E

120.0k110.0k101.0k
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(4.6m)(81.7m)(43.8m)(79.2m)(100.8m)

Depreciation and Amortization

17.0k41.0k

Accounts Payable

60.0k1.3m(426.0k)2.5m3.3m

Cash From Operating Activities

(4.4m)(4.6m)(35.6m)(70.8m)(79.7m)
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

(28.1m)(11.9m)(28.1m)(15.1m)(44.0m)(68.4m)(26.0m)

Depreciation and Amortization

11.0k21.0k30.0k11.0k

Accounts Payable

(1.3m)588.0k1.6m1.2m(1.1m)3.5m(2.2m)

Cash From Operating Activities

(24.0m)(11.3m)(33.9m)(18.3m)(38.4m)(53.0m)(22.9m)
USDFY, 2017

Financial Leverage

1.5 x
Show all financial metrics

Akero Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Akero Securities Corporation

Akero Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Akero Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Akero Therapeutics Online and Social Media Presence

Embed Graph

Akero Therapeutics News and Updates

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis

Post hoc analysis shows potential for EFX to treat patients at highest genetic risk for progressive and advanced NASH Post hoc analysis shows potential for EFX to treat patients at highest genetic risk for progressive and advanced NASH

Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH

Presentations to highlight the association of EFX’s antifibrotic effects as scored by histology with consistent reductions in biomarkers of liver collagen synthesis Presentations to highlight the association of EFX’s antifibrotic effects as scored by histology with consistent reductions in biomarker…

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at th…

Akero Therapeutics Reports First Quarter 2022 Financial Results

Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year

Akero Therapeutics to Present at Upcoming Healthcare Conferences in May

SOUTH SAN FRANCISCO, May 02, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in the fol…

Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year
Show more

Akero Therapeutics Blogs

Efruxifermin is Associated With Improved Glucose Metabolism in Patients With NASH and Type 2 Diabetes

Frias, J. et al. (2021) ADA Scientific Sessions The post Efruxifermin is Associated With Improved Glucose Metabolism in Patients With NASH and Type 2 Diabetes first appeared on Akero.

Increased adiponectin following efruxifermin treatment is associatedwith improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NASH

Frias, J. et al. (2021) ADA Scientific Sessions The post Increased adiponectin following efruxifermin treatment is associatedwith improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NASH first appeared on Akero.

Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, and metabolism, and in histologic parameters following treatment with efruxifermin

Harrison, S. et al. (2021) EASL The post Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, and metabolism, and in histologic parameters following treatment with efruxifermin first appeared on Akero.

The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial

Loomba, R. et al. (2021) EASL The post The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial first appeared on Akero.
Show more

Akero Therapeutics Frequently Asked Questions

  • When was Akero Therapeutics founded?

    Akero Therapeutics was founded in 2017.

  • Who are Akero Therapeutics key executives?

    Akero Therapeutics's key executives are Jonathan Young, Mark Iwicki and William White.

  • How many employees does Akero Therapeutics have?

    Akero Therapeutics has 13 employees.

  • Who are Akero Therapeutics competitors?

    Competitors of Akero Therapeutics include Onsite Health Diagnostics, PECAA and Surya Dermato Medica Laboratories.

  • Where is Akero Therapeutics headquarters?

    Akero Therapeutics headquarters is located at 170 Harbor Way 3rd Floor, San Francisco.

  • Where are Akero Therapeutics offices?

    Akero Therapeutics has offices in San Francisco, Cambridge and South San Francisco.

  • How many offices does Akero Therapeutics have?

    Akero Therapeutics has 3 offices.